{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"groups":[{"description":"Bortezomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"BG000","title":"[VRd]; Bortezomib + Lenalidomide + Dexamethasone Therapy"},{"description":"Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"BG001","title":"[KRd]; Carfilzomib + Lenalidomide + Dexamethasone Therapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.57","value":"71.8"},{"groupId":"BG001","spread":"9.40","value":"70.5"},{"groupId":"BG002","spread":"9.21","value":"70.7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"21"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"24"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Japan"}],"description":"All participants were enrolled in Japan.","paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.70","value":"153.0"},{"groupId":"BG001","spread":"8.29","value":"158.5"},{"groupId":"BG002","spread":"8.58","value":"157.8"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Height","unitOfMeasure":"Centimeters (cm)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.204","value":"52.85"},{"groupId":"BG001","spread":"10.380","value":"57.87"},{"groupId":"BG002","spread":"10.081","value":"57.17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"43"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"Weight","unitOfMeasure":"Kilograms (kg)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"2.619","value":"22.60"},{"groupId":"BG001","spread":"2.512","value":"22.91"},{"groupId":"BG002","spread":"2.497","value":"22.86"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"43"}],"units":"Participants"}]}],"description":"Body Mass Index = weight (kg)/\\[height (m)\\^2\\]","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"BMI","unitOfMeasure":"Kilogram (kg)/meter (m)^2]"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.1395","value":"1.487"},{"groupId":"BG001","spread":"0.1760","value":"1.583"},{"groupId":"BG002","spread":"0.1732","value":"1.569"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"43"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"Body Surface Area","unitOfMeasure":"m^2"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"19"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"9"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Stage III"}],"description":"International Staging System is a staging system for cancer progression. Stages are classified by Stage I to Stage III. Stage I: Serum beta2-microglobulin \\<3.5 mg/L and albumin ≥3.5 g/dL; Stage II: Neither Stage I or III, meaning that either: beta2-microglobulin level ≥3.5 and \\<5.5 mg/L (with any albumin level), OR albumin \\<3.5 g/dL with beta2-microglobulin \\<3.5 mg/L; Stage III: Serum beta2-microglobulin ≥5.5 mg/L. Normal serum beta2-microglobulin: \\<3.0 mg/L; normal albumin: 3.5-5.0 g/dL.","paramType":"COUNT_OF_PARTICIPANTS","title":"International Staging System (at Initial Diagnosis)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"24"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"13"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Missing"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"International Staging System (at First Treatment [Period I])","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"33"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Scale = 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"10"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Scale = 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Scale = 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Scale = 3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"45"}],"units":"Participants"}],"title":"Scale = 4"}],"description":"ECOG P.S.) assess participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory ( greater than \\[\\>\\] 50 percent \\[%\\] of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self-care, confined to bed/chair \\>50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5=dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group performance status (ECOG P.S.)","unitOfMeasure":"Participants"}],"populationDescription":"Full Analysis Set (FAS): all participants who were enrolled in Treatment Period I and who receive at least one dose of any therapy during the Treatment Period."}